The cellular kinetics and significance of intra-tumoral immune cells within oral squamous cell carcinomas

口腔鳞状细胞癌瘤内免疫细胞的细胞动力学和意义

• 批准号: 21890157
• 负责人: TAKESUE Nanako
• 金额: $ 1.66万
• 依托单位: Hiroshima University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Research Activity Start-up
• 财政年份: 2009
• 资助国家: 日本
• 起止时间: 2009 至 2010
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-21890157/
• 关键词: メモリーT細胞; sMICA; hnRNPLL; CD45RO; メモリー細胞

The MICA (MHC class I chain-related molecule A) is the ligand of NKG2D, which is activation receptor on most NK cells and antigen-specific effector T cells. These molecules are absent from most cells but can be induced by stress, infection, cell transformation, and are frequently expressed in epithelial tumors. On the other hand, it has been speculated that tumors have ways of evading the body's immune system. As one of the system of this, there are soluble forms of MICA (sMICA) in the serum which can affect NKG2D function by blocking recognition of membrane-bound MICA and down-regulation of NKG2D. As a result, NK cells etc. effectively become blind to the presence of tumor. Serum sMICA level may serve as a novel molecular target/biomarker of OSCC for its diagnosis, therapy, and prognosis. Recently, it has been shown that immune cells within distinct tumor regions could provide a prognostic factor superior to and independent of criteria related to the anatomic extent of the tumor.

MICA （MHC I类链相关分子A）是NKG2D的配体，是大多数NK细胞和抗原特异性效应T细胞的激活受体。这些分子在大多数细胞中不存在，但可以被应激、感染、细胞转化诱导，并且经常在上皮肿瘤中表达。另一方面，有人推测肿瘤有逃避人体免疫系统的方法。其中，血清中存在可溶性MICA (sMICA)，通过阻断膜结合MICA的识别，下调NKG2D，从而影响NKG2D的功能。因此，NK细胞等有效地对肿瘤的存在视而不见。血清sMICA水平可作为OSCC诊断、治疗和预后的新的分子靶点/生物标志物。最近，研究表明，不同肿瘤区域内的免疫细胞可以提供优于且独立于肿瘤解剖范围相关标准的预后因素。